Saman Hayatdavoudi, MD
Critical Care Medicine · Sacramento, CANPI 1093912958
Payments from drug & device makers
Across 227 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$795
- Boehringer Ingelheim$700
- Merck$260
- Actelion Pharmaceuticals US, Inc.$194
- United Therapeutics Corporation$158
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,967100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $1,088 |
| AstraZeneca(2 entities) | 37 | $795 |
| Boehringer Ingelheim | 31 | $700 |
| Merck | 11 | $260 |
| Actelion Pharmaceuticals US, Inc. | 7 | $194 |
| United Therapeutics Corporation | 7 | $158 |
| Electromed, Inc. | 6 | $148 |
| Sanofi | 5 | $143 |
| AbbVie(2 entities) | 7 | $137 |
| Regeneron Healthcare Solutions, Inc. | 5 | $129 |
| Mylan Specialty L.p. | 6 | $105 |
| Baxter Healthcare | 6 | $104 |
| Inari Medical, Inc. | 1 | $85 |
| Inspire Medical Systems, Inc. | 2 | $79 |
| Amgen | 3 | $68 |
| Philips North America LLC | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 7 | $62 |
| Insmed, Inc. | 2 | $50 |
| Harmony Biosciences LLC | 2 | $46 |
| Paratek Pharmaceuticals, Inc. | 2 | $45 |
| Pulmonx Corporation | 2 | $42 |
| Gilead | 2 | $42 |
| Bayer | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| Grifols USA, LLC | 2 | $37 |
| Novartis | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Advanced Respiratory, Inc | 2 | $25 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| Viiv Healthcare Company | 1 | $22 |
| Kaleo, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
How this compares
$4,967 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 314 | $223,132 |
| Breo ElliptaFluticasone/Vilanterol | 170 | $84,697 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $29,436 |
| Spiriva RespimatTiotropium Bromide | 45 | $27,061 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,567 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 265 | $7,252 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 16 | $7,194 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,161 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $3,569 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,413 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $2,339 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,453 |
| Azithromycin | 31 | $377 |
| Montelukast Sodium | 39 | $327 |
| Prednisone | 89 | $250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,088 | $315,397497 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $795 | $33,59663 claims |
| Boehringer IngelheimSpiriva Respimat | $700 | $27,06145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Sacramento
- Timothy AlbertsonSacramento$7.6M
- Ken YonedaSacramento$545K
- Chinh PhanSacramento$467K
- Muhammad AfzalSacramento$72K
- Nicholas KenyonSacramento$29K
- Rafael LupercioRedding$14.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.